Table 3 Associations between the expression level of EGFR pathway genes and EGFR inhibitor responses predicted by ML-CDN2
From: Predicting breast cancer drug response using a multiple-layer cell line drug response network model
Drug | Gene | Adjusted p-value |
|---|---|---|
Erlotinib | ADCY7 | 1.51 × 10−3 |
CDK1 | 2.00 × 10−31 | |
FOXO1 | 4.22 × 10−2 | |
MAPK1 | 1.02 × 10−2 | |
PAG1 | 2.64 × 10−3 | |
Afatinib | ADAM12 | 1.64 × 10−5 |
ADCY7 | 4.63 × 10−4 | |
CDK1 | 8.88 × 10− 3 | |
EGF | 2.94 × 10− 2 | |
Cetuximab | ADCY6 | 2.67 × 10− 2 |
ADRBK1 | 1.02 × 10− 2 | |
CDK1 | 1.59 × 10−19 | |
SPRY2 | 2.18 × 10− 4 | |
Lapatinib | AKT3 | 8.00 × 10−3 |
CDK1 | 5.68 × 10−17 | |
ITPR2 | 2.39 × 10−5 | |
CP724714 | CDK1 | 6.22 × 10−9 |
FOXO1 | 3.18 × 10−2 | |
PDPK1 | 2.17 × 10−2 | |
Pelitinib | ADCY9 | 4.06 × 10−4 |
CDK1 | 9.07 × 10−5 | |
EGFR | 2.90 × 10−2 | |
ITPR3 | 3.03 × 10−3 | |
PAG1 | 3.87 × 10−2 | |
PIK3R1 | 1.04 × 10−2 |